The future use of complement inhibitors for the treatment of neurological diseases

Drugs

Volumn 55, Issue 6, 1998, Pages 739-746

  McGeer, Edith G ^a   McGeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; IMMUNOMODULATING AGENT; OXYGEN RADICAL;

ALZHEIMER DISEASE; ARTICLE; BRAIN ISCHEMIA; CELL KILLING; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNE RESPONSE; MACROPHAGE; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; XENOTRANSPLANTATION;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOTOXICITY, IMMUNOLOGIC; GRAFT REJECTION; HUMANS; ORGAN TRANSPLANTATION; REPERFUSION INJURY;

ANIMALIA;

EID: 0031804455     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855060-00001     Document Type: Article

References (62)

1. Morgan BP. Clinical complementology: recent progress and future trends. Eur J Clin Invest 1994; 24: 219-28
2. Ridker PM, Manson JE, Gaziano JM, et al. Low-dose aspirin therapy for chronic stable angina: a randomized placebo-controlled clinical trial. Ann Intern Med 1991; 114: 835-9
3. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 1996; 47: 425-32
4. Verry M, Panak E, Cazenave JP. Antiplatelet therapy in the prevention of ischaemic stroke. Nouv Rev Fr Hematol 1994; 36: 213-28
5. Hershey LA. Stroke prevention in women: role of aspirin versus ticlopidine. Am J Med 1991; 91: 288-92
6. Heath Jr CW. Rheumatoid arthritis, aspirin and gastrointestinal cancer. J Natl Cancer Inst 1993; 85: 258-9
7. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 1996; 7: 203-5
8. Harding JJ. Pharmacological treatment strategies in age-related cataracts. Drugs Aging 1992; 2: 287-300
9. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-11
10. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995; 21: 195-218
11. Sapolsky RM, Uno H, Robert CS, et al. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci 1990; 10: 2897-902
12. Morgan BP. Physiology and pathophysiology of complement: progress and trends. Crit Rev Clin Lab Sci 1995; 32: 265-98
13. Taupenot L, Ciesielski-Traska J, Ulrich G, et al. Chromogranin A triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells. Neuroscience 1996; 72: 377-89
14. Klegeris A, Walker DG, McGeer PL. Activation of macrophages by Alzheimer β amyloid peptide. Biochem Biophys Res Commun 1994; 199: 984-91
15. McGeer EG, McGeer PL. The role of the immune system in neurodegenerative disorders. Movement Disorders 1997; 12: 855-8
16. Matsuura K, Kabuto H, Makino H, et al. Cyclosporin A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine in the mouse brain. Brain Res 1996; 733: 101-4
17. Kitamura Y, Itano Y, Kubo T, et al. Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. J Neuroimmunol 1994; 50: 221-4
18. Matsuura K, Makino H, Ogawa N. Cyclosporin A attenuates the decreases in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injections of 6-hydroxydopamine. Exp Neurol 1997; 146: 526-35
19. Matsuura K, Kabuto H, Makino H, et al. Initial cyclosporin A but not glucocorticoid treatment promotes recovery of striatal dopamine concentration in 6-hydroxydopamine lesioned mice. Neurosci Lett 1997; 230: 191-4
20. Boireau A, Bordier F, Dubedat P, et al. Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. Neurosci Lett 1997; 234: 123-6
21. Shiga Y, Onodera H, Matsuo Y, et al. Cyclosporin A protects against ischemia-reperfusion injury in the brain. Brain Res 1992; 595: 145-8
22. Ogawa N, Tanaka K, Kondo Y, et al. The preventative effect of cyclosporin A, an immunosuppressant, on the late onset reduction of muscarinic acetylcholine receptors in gerbil hippocampus after transient forebrain ischemia. Neurosci Lett 1993; 152: 173-6
23. Kondo Y, Ogawa N, Asanuma M, et al. Cyclosporin A prevents ischemia-induced reduction of muscarinic acetylcholine receptors with suppression of microglial activation in gerbil hippocampus. Neurosci Res 1995; 22: 123-7
24. Li P-A, Uchino H, Elmer E, et al. Amelioration by cyclosporin A of brain damage following 5 or 10 min of ischemia in rats subjected to preischemic hyperglycemia. Brain Res 1997; 753: 133-40
25. Asanuma M, Asanuma SN, Gomez-Vargas M, et al. Ketoprofen, a non-steroidal anti-inflammatory drug, prevents the late-onset reduction of muscarinic receptors in gerbil hippocampus after transient forebrain ischemia. Neurosci Lett 1997; 225: 109-12
26. Shen Y, Li R, McGeer EG, et al. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer hrain. Brain Res 1997; 769: 391-5
27. Terai K, McGeer EG, McGeer PL. Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res 1997; 769: 385-90
28. Passwell J, Schreiner GF, Nonaka M, et al. Local extrahepatic expression of complement genes C3, factor B, C2 and C4 is increased in murine lupus nephritis. J Clin Invest 1988; 82: 1676-84
29. Liszewski MK, Farries TC, Lublin DM, et al. Control of the complement system. Adv Immunol 1996; 61: 201-83
30. Rey-Campos J, Rubinstein P, Rodriguez de Cordoba S. Decay-accelerating factor: genetic polymorphism and linkage to the RCA (regulator of complement activation) gene cluster in humans. J Exp Med 1987; 166: 246-52
31. Carroll MC, Alicot EM, Katzman PJ, et al. Organization of the genes encoding complement receptors type 1 and 2, decay-accelerating factor, and C4-binding protein in the RCA locus on human chromosome 1. J Exp Med 1988; 167: 1271-80
32. Campbell RD, Law SK, Reid KB, et al. Structure, organization, and regulation of the complement genes. Annu Rev Immunol 1988; 6: 161-95
33. Hourcade D, Holders VM, Atkinson JP. The regulators of complement activation (RCA) gene cluster. Adv Immunol 1989; 45: 381-416
34. Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994; 15: 369-96
35. Podack ER, Kolb WP, Müller-Eberhard HJ. The SC5b-7 complex: formation, isolation, properties and subunit composition. J Immunol 1977; 119: 2024-9
36. Murphy BF, Saunders JR, O'Bryan MK, et al. SP-40,40 is an inhibitor of C5b-6-initiated haemolysis. Int Immunol 1989; 1: 551-4
37. Choi NH, Mazda T, Tomita M. A serum protein SP40,40 modulates the formation of membrane attack complex on erythrocytes. Mol Immunol 1989; 26: 835-40
38. Jenne DE, Tschopp J. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Soc Natl Acad Sci USA 1989; 86: 7123-7
39. Rollins SA, Zhao J, Ninomiya H, et al. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within V5b-8 or C9 within C5b-9. J Immunol 1991; 146: 2345-51
40. Rother RP, Rollins SA, Fodor WL, et al. Inhibition of complement-mediated cytolysis by the terminal complement inhibitor of herpesvirus saimiri. J Virol 1994; 68: 730-7
41. Agoropoulos C, Wing MG, Wood A. CD59 expression and complement susceptibility of human neuronal cell lines. Neuroreport 1996; 7: 997-1004
42. Byrne GW, McCurry KR, Martin MJ, et al. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997; 63: 149-55
43. Christensen D, Milland J, Thorley BR, et al. Engineering of recombinant soluble CD46: an inhibitor of complement activation. Immunology 1996; 87: 348-54
44. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995; 91: 393-402
45. Flynn DM, Buda A, Jeffords PR, et al. A sialyl Lewis-containing carbohydrate reduces infarct size: role of selectins in myocardial reperfusion injury. Am J Physiol 1996; 271: H2086-96
46. Mulligan MS, Watson SR, Fennie C, et al. Protective effects of selectin chimeras in neutrophil-mediated lung injury. J Immunol 1993; 151: 6410-7
47. Weissman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146-51
48. Mulligan MS, Yeh C, Rudolph AR, et al. Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury. J Immunol 1992; 148: 1479-85
49. Davis EA, Pruitt SK, Greene PS, et al. Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts. Transplantation 1996; 62: 1018-23
50. Marsh HC, Ryan US. Therapeutic effect of soluble complement receptor type 1 in xenotransplantation. In: Cooper DKC, Kemp E, Platt JL, et al., editors. Xenotransplantation: the transplantation of organs and tissues between species. Berlin: Springer, 1997: 437-55
51. Kalli KR, Hsu P, Fearon DT. Therapeutic uses of recombinant complement protein inhibitors. Springer Semin Immunopathol 1994; 15: 417-31
52. Homeister JW, Lucchesi BR. Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxical 1994; 34: 17-40
53. Ryan US. Complement inhibitory therapeutics and xenotransplantation. Nature Med 1995; 1: 967-8
54. Kirschfink M. Controlling the complement system in inflammation. Immunopharmacology 1997; 38: 51-62
55. Higgins PJ, Ko JL, Lobell R, et al. A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor 1 cofactor activities. J Immunol 1997; 158: 2872-81
56. Wang Y, Rollins SA, Madri JA, et al. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995; 92: 8955-9
57. Hagmann WK, Sindelar RD. Potential therapeutic modifiers of the complement cascade. Annu Rep Med Chem 1992; 27: 199-208
58. Gridelli B, Gatti S, Andreani P, et al. Xenogenetic orthotopic liver transplantation from sheep to pig: delay of rejection by FUT 175 infusion. Transplantation Proc 1996; 28: 784-7
59. Miyagawa S, Shirakura R, Matsumiya G, et al. Prolonging discordant xenograft survival with anticomplement reagents K76COOH and FUT175. Transplantation 1993; 55: 709-13
60. Fujita Y, Inoue I, Inagi R, et al. Inhibitory effect of FUT-175 on complement activation and its application for glomerulonephritis with hypocomplementemia. Jpn J Nephrology 1993; 35: 393-7
61. Ekre HP, Fjellner B, Hagermark O. Inhibition of complement dependent experimental inflamation in human skin by different heparin fractions. Int J Immunopharmacol 1986; 8: 277-86
62. Gralinski MR, Park JL, Ozeck MA, et al. LU 51198, a highly sulfated, low-molecular-weight heparin derivative, prevents complement-mediated myocardial injury in the perfused rabbit heart. J Pharm Exp Ther 1997; 282: 554-60